Investigating the effects of psychoactive agents on Alzheimer's disease
Cross platform analysis of drug targets and toxicity of bath salts
['FUNDING_U01'] · UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS · NIH-10939799
This study is looking at how certain hallucinogenic substances might help improve brain health and thinking skills in people with Alzheimer's by exploring how they affect brain cells and their connections.
Quick facts
| Phase | ['FUNDING_U01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS (nih funded) |
| Locations | 1 site (TOLEDO, UNITED STATES) |
| Trial ID | NIH-10939799 on ClinicalTrials.gov |
What this research studies
This research explores how certain psychoactive substances, particularly hallucinogens, can influence brain changes related to Alzheimer's disease. By examining the mechanisms of these substances, the study aims to understand their potential to promote synaptic plasticity and improve cognitive function in patients. The approach involves analyzing human-derived cells from Alzheimer's patients to assess how these agents interact with specific cellular pathways and gene expressions. The research utilizes advanced techniques to provide a comprehensive view of the effects of these substances on brain health.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or related dementias.
Not a fit: Patients with non-Alzheimer's forms of dementia or those without cognitive impairments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies for treating Alzheimer's disease and improving cognitive function.
How similar studies have performed: While the approach of using psychoactive agents in the context of Alzheimer's is relatively novel, there is emerging evidence suggesting potential benefits from similar investigations in neuropsychiatric disorders.
Where this research is happening
TOLEDO, UNITED STATES
- UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS — TOLEDO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SCHIEFER, ISAAC T — UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS
- Study coordinator: SCHIEFER, ISAAC T
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Alzheimer disease dementia, Alzheimer syndrome, Alzheimer's Disease, Alzheimer's disease model, Alzheimer's disease patient